Medical Center Comac Medical Ltd.

The research at Medical Center Comac Medical Ltd. includes detailed pharmacokinetic investigations to understand how liver and kidney conditions affect drug behavior, with a focus on therapies relevant to the digestive system.

• Impact of hepatic impairment on drug absorption and clearance
• Influence of renal impairment on drug exposure levels
• Safety and tolerability profiling in healthy volunteers

The site is conducting three trials with two investigators, examining agents such as AMX0035 and Camizestrant to improve treatment strategies for patients with liver or kidney dysfunction.

This area concentrates on multiple‑dose studies that compare drug performance in participants with organ impairment versus healthy subjects, aiming to refine dosing recommendations.

• Multiple dose pharmacokinetic profiling in impaired renal function
• Evaluation of hepatic function effects on drug safety in post‑menopausal women
• Comparative analysis of drug exposure between impaired and healthy volunteers

With three active trials, the center supports the development of safer and more effective therapies by assessing how hepatic and renal conditions modify drug behavior.